At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating ...

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She's a certified sleep science coach and ...

Eli Lilly has disclosed in a civil lawsuit filed in federal court on Tuesday that a rebate fraud scheme cost it more than $200 million. The company alleges several bishops and a leader of the Church ...

Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare. The Centers for Medicare & Medicaid Services (CMS), the federal agency that ...

The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications Botox and ...

The new cycle of Medicare drug price negotiations includes 15 high-cost drugs, with some covered under Medicare Part B for the first time. The negotiations, part of the Inflation Reduction Act, aim to ...

The popular type 2 diabetes drug dulaglutide (Trulicity), botulinum toxin (Botox), and drugs to treat psoriatic arthritis, prostate cancer, and breast cancer are among the 15 drugs that the Centers ...

The Centers for Medicare and Medicaid Services (CMS) have announced the next 15 drugs whose prices will be negotiated as part of the third round of Medicare negotiations. This latest round of ...

The US plans to slash the price it pays for Botox and diabetes drug Trulicity, the latest medicines to be targeted under legislation that’s expected to save the government more than $200 billion over ...

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. WASHINGTON — The Trump ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors.